普罗托帕纳克萨迪醇改善了INS-1细胞中棕酸盐诱导的脂毒性和胰腺β细胞功能障碍
Dahae Lee1, Sungyoul Choi1, Ki Sung Kang1
1College of Korean Medicine, Gachon University, Seongnam, Republic of Korea.
Journal of ginseng research
|July 3, 2023
概括
蛋白松醇 (PPD) 保护胰腺β细胞免受棕酸诱导的脂毒性. 通过减少脂质积累和亡,PPD减少细胞死亡,改善胰岛素分泌.
科学领域:
- 内分泌学 在内分泌学.
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 自由脂肪酸诱导的脂毒性有助于胰腺β细胞功能障碍.
- 暴露于棕酸会损害β细胞功能和胰岛素分泌.
研究的目的:
- 为了评估金氏化物对棕酸诱导的胰腺β细胞死亡和葡萄糖刺激胰岛素分泌 (GSIS) 的影响.
- 来识别用于治疗脂毒性,从人参化物中发现潜在的治疗剂.
主要方法:
- 选人参化物对INS-1胰腺β细胞的保护作用.
- 使用胰岛素ELISA套件量化GSIS.
- 通过染色和西部涂抹评估亡,脂质积累和蛋白质表达.
主要成果:
- 鉴定出普托帕纳克萨迪 (PPD) 是一种潜在的治疗剂,可以预防棕酸诱导的细胞死亡和GSIS损伤.
- PPD减少了β细胞中的亡和脂质积累.
- PPD调节了与亡相关的蛋白质 (Bcl-2,PARP,caspase-3) 和信号通路 (PI3K,PPARγ,IRS-2,Akt,PDX-1). 这两种蛋白质的作用是:
结论:
- PPD对棕酸诱导的脂毒性和胰腺β细胞中的脂质积累具有保护作用.
- PPD证明了对管理与脂质毒性相关的β细胞功能障碍的治疗潜力.
更多相关视频
08:20Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
Published on: December 2, 2022
1.9K
08:35A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
Published on: May 18, 2021
6.4K
相关概念视频
Insulin: Biosynthesis, Chemistry, and Preparation
437
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
437
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Glucagon-like Receptor Agonists
365
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
365
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
